Literature DB >> 2524997

Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests.

A L Barry1, R N Jones, C Thornsberry.   

Abstract

The in vitro activities of trospectomycin sulfate were compared with those spectinomycin against 632 aerobic microorganisms, including 66 Neisseria gonorrhoeae isolates. Against species other than gram-negative bacilli, trospectomycin was about 4- to 16-fold more active than spectinomycin. For disk diffusion tests, a 30-micrograms disk is recommended, with tentative zone size breakpoints of less than or equal to 13 mm for resistance (MIC, greater than or equal to 64 micrograms/ml) and greater than or equal to 17 mm for susceptibility (MIC, less than or equal to 16 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524997      PMCID: PMC172481          DOI: 10.1128/AAC.33.4.569

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog.

Authors:  G E Zurenko; B H Yagi; J J Vavra; B B Wentworth
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

2.  Synthesis and in vitro antibacterial properties of alkylspectinomycin analogs.

Authors:  D R White; C J Maring; G A Cain
Journal:  J Antibiot (Tokyo)       Date:  1983-03       Impact factor: 2.649

3.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  Spectinomycin modification. III. Spectinomycin analogs with C-3'-branched chain sugars.

Authors:  R C Thomas; E L Fritzen
Journal:  J Antibiot (Tokyo)       Date:  1985-02       Impact factor: 2.649

6.  In-vitro activity of trospectomycin sulphate against Mycoplasma and Ureaplasma species isolated from humans.

Authors:  R J Yancey; L K Klein
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

  6 in total
  8 in total

1.  Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

3.  Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections.

Authors:  David F Bruhn; Samanthi L Waidyarachchi; Dora B Madhura; Dimitri Shcherbakov; Zhong Zheng; Jiuyu Liu; Yasser M Abdelrahman; Aman P Singh; Stefan Duscha; Chetan Rathi; Robin B Lee; Robert J Belland; Bernd Meibohm; Jason W Rosch; Erik C Böttger; Richard E Lee
Journal:  Sci Transl Med       Date:  2015-05-20       Impact factor: 17.956

4.  Structural Recognition of Spectinomycin by Resistance Enzyme ANT(9) from Enterococcus faecalis.

Authors:  Sandesh Kanchugal P; Maria Selmer
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).

Authors:  T U Westblom; B R Midkiff; S J Czinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

6.  Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

8.  Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.

Authors:  K Vogt; A C Rodloff; H Hahn
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.